CSL Executive VEEP: Leaders lead during uncertainty - there is no question that we are all experiencing the impact of COVID-19
CSL Behring and Takeda Pharmaceutical Company Limited are leading a joint effort with Biotest, BPL Group, LFB, and Octapharm to develop a potential plasma-derived therapy for treating COVID-19. The
alliance started immediately with the investigational development of
one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin
medicine with the potential to treat individuals with serious
complications from COVID-19.
“Leaders lead during uncertainty. There is no question that we are all experiencing the impact of COVID-19,” said Bill Mezzanotte, CSL Behring’s Executive Vice President and Head of Research and Development.Read more from B. Mezzanote.
“Leaders lead during uncertainty. There is no question that we are all experiencing the impact of COVID-19,” said Bill Mezzanotte, CSL Behring’s Executive Vice President and Head of Research and Development.Read more from B. Mezzanote.
